Dr. Brian Steingo, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 55
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 182
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME0036908
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Boca Raton Regional Hospital Boca Raton, FL
Medical groups
- Neuroscience Consultants LLP (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 586
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 214 | 140 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 93 |
| Insertion of needle into vein for collection of blood sample | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Boca Raton, FL | 166 |
| Baclofen Other prescribers in Boca Raton, FL | 128 |
| Copaxone (glatiramer acetate) | 127 |
| Kesimpta Pen (ofatumumab) | 91 |
| Teriflunomide | 89 |
| Tizanidine Hcl Other prescribers in Boca Raton, FL | 85 |
| Alprazolam Other prescribers in Boca Raton, FL | 81 |
| Dalfampridine Er (dalfampridine) | 67 |
| Clonazepam Other prescribers in Boca Raton, FL | 62 |
| Dextroamphetamine-Amphetamine (dextroamphetamine/amphetamine) Other prescribers in Boca Raton, FL | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 177 payments worth $64,336 in total to this clinician.
| EMD Serono, Inc. | $29,048 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $24,426 |
| Genentech USA, Inc. | $8,223 |
| Biogen, Inc. | $719 |
| Genentech, Inc. | $227 |
| Mallinckrodt Hospital Products Inc. | $226 |
| Genzyme Corporation | $207 |
| Tg Therapeutics, Inc. | $166 |
| Compensation for services other than consulting (speaking, faculty) | $50,861 |
|---|---|
| Consulting Fee | $6,675 |
| Food and Beverage | $4,880 |
| Travel and Lodging | $1,809 |
| Education | $112 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $8,628 |
| Genentech USA, Inc. Oct 4, 2025 | Consulting Fee | $6,525 |
| EMD Serono, Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $4,463 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,260 |
| Alexion Pharmaceuticals, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. May 9, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| EMD Serono, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $3,273 |
All 32 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| EMD Serono, Inc. Dec 30, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $595 |
| EMD Serono, Inc. Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $3,273 |
| EMD Serono, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $3,273 |
| Alexion Pharmaceuticals, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging travel to Miami Lakes, FL | $46.62 |
| Alexion Pharmaceuticals, Inc. Oct 17, 2025 | Travel and Lodging travel to Miami Lakes, FL | $2.32 |
| Genentech USA, Inc. Oct 4, 2025 | Consulting Fee | $6,525 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $715 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $371 |
| Genentech USA, Inc. Oct 4, 2025 | Travel and Lodging travel to Denver, CO | $103 |
| EMD Serono, Inc. Sep 17, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $4,463 |
| EMD Serono, Inc. Sep 10, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaking Services (Fee For Service) | $3,273 |
| Mallinckrodt Hospital Products Inc. Aug 19, 2025 | Education ACTHAR · IMMUNOLOGY · in-kind Company’s descriptionRelevant medical textbook or clinical reprint | $98.99 |
| Alexion Pharmaceuticals, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $4,260 |
| EMD Serono, Inc. Jul 1, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $3,273 |
| Alexion Pharmaceuticals, Inc. Jun 25, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Stuart, FL | $112 |
| EMD Serono, Inc. Jun 11, 2025 | Education in-kind Company’s descriptionReprints | $12.56 |
| Biogen, Inc. May 29, 2025 | Consulting Fee TYSABRI · Neurology | $150 |
| Alexion Pharmaceuticals, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $1,775 |
| EMD Serono, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $8,628 |
| Alexion Pharmaceuticals, Inc. May 9, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. May 9, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Weston, FL | $20.58 |
| Alexion Pharmaceuticals, Inc. May 9, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Weston, FL | $2.32 |
| Alexion Pharmaceuticals, Inc. Apr 14, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Apr 14, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Miami, FL | $58.66 |
| Alexion Pharmaceuticals, Inc. Apr 14, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Miami, FL | $2.32 |
| EMD Serono, Inc. Apr 4, 2025 | Travel and Lodging travel to Dallas, TX Company’s descriptionSpeaking Services (Lodging) | $319 |
| Alexion Pharmaceuticals, Inc. Mar 6, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Mar 1, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Weston, FL | $20.58 |
| Alexion Pharmaceuticals, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Feb 13, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boca Raton, FL | $34.72 |
| EMD Serono, Inc. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) Mavenclad · Neurology Company’s descriptionSpeaker Training (Fee For Service) | $298 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $275,715 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
Novartis Pharmaceuticals Corporation - Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)
Genzyme Corporation · Completed · NCT04410991 - A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Scle…
Amgen Inc. - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study)
EMD Serono, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.